Transaction details
Martine Rothblatt, who serves as Chairperson and Chief Executive Officer of United Therapeutics (NASDAQ: UTHR), sold a total of $5.1 million in common stock across transactions dated March 12 and March 16, 2026. The sale prices spanned from $532.16 to $544.5849 per share.
The individual share sales recorded on March 12 included: 640 shares, 60 shares, 1,955 shares, 1,772 shares, 1,077 shares, 720 shares, 1,240 shares, 400 shares, 600 shares, 356 shares and 164 shares. On March 16, Rothblatt sold an additional 516 shares.
Also on March 16, Rothblatt exercised stock options, acquiring 9,500 shares of United Therapeutics common stock at an exercise price of $146.03 per share, representing a total exercise amount of $1,387,285.
Those sales and the option exercise were executed under a pre-arranged 10b5-1 trading plan that was adopted on November 7, 2025. Following the completion of these transactions, Rothblatt directly holds 294 shares of United Therapeutics common stock. She also retains indirect holdings through various trusts.
Corporate developments and clinical progress
Ahead of and alongside the insider transactions, United Therapeutics has moved forward on several strategic and clinical fronts. The company announced a new $2 billion share repurchase program. As part of that program, United Therapeutics entered into initial accelerated share repurchase agreements with Citibank totaling $1.5 billion, leaving $500 million available for further repurchases at the company's discretion.
Market analysts have reacted to the company’s developments. TD Cowen interpreted the repurchase program as a sign of confidence in the company’s franchise and maintained a Buy rating with a $575 price target. Cantor Fitzgerald also adjusted its outlook, raising its price target to $625 from $525 while maintaining an Overweight rating, citing positive expectations stemming from the TETON-1 trial.
On the clinical front, results from United Therapeutics’ phase 3 TETON-2 study were published in the New England Journal of Medicine. The trial evaluated nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis and met its primary endpoint, showing a statistically significant improvement in lung function compared with placebo over a 52-week period.
Context and factual constraints
The reporting above is limited to the details provided by the company filings and announcements. No additional inferences are made beyond the stated transactions, ownership figures, repurchase program terms, analyst ratings, price targets, and clinical-trial outcomes as described.